Rosalind Advisors Inc. Has $6.97 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)

Rosalind Advisors Inc. lowered its position in shares of Verona Pharma plc (NASDAQ:VRNA) by 45.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 150,000 shares of the company’s stock after selling 125,000 shares during the quarter. Verona Pharma makes up about 3.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 12th largest position. Rosalind Advisors Inc.’s holdings in Verona Pharma were worth $6,966,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in VRNA. GAMMA Investing LLC raised its position in shares of Verona Pharma by 20.7% in the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company’s stock valued at $75,000 after acquiring an additional 276 shares during the period. EMC Capital Management boosted its stake in shares of Verona Pharma by 3,400.0% during the 4th quarter. EMC Capital Management now owns 3,500 shares of the company’s stock worth $163,000 after acquiring an additional 3,400 shares during the period. Wrapmanager Inc. bought a new position in Verona Pharma in the 4th quarter valued at about $207,000. Transcend Capital Advisors LLC bought a new position in shares of Verona Pharma during the fourth quarter worth approximately $225,000. Finally, Raymond James Financial Inc. bought a new position in Verona Pharma in the 4th quarter valued at about $225,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analysts Set New Price Targets

VRNA has been the topic of a number of recent research reports. Wells Fargo & Company increased their target price on Verona Pharma from $74.00 to $93.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial reiterated a “buy” rating and issued a $57.00 target price (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Roth Mkm began coverage on shares of Verona Pharma in a report on Friday, January 10th. They set a “buy” rating and a $68.00 price target on the stock. Canaccord Genuity Group boosted their price target on shares of Verona Pharma from $44.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Finally, HC Wainwright increased their price objective on Verona Pharma from $60.00 to $75.00 and gave the company a “buy” rating in a report on Friday, February 28th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $69.14.

Verona Pharma Price Performance

VRNA stock opened at $66.81 on Friday. The firm has a market capitalization of $5.40 billion, a P/E ratio of -34.80 and a beta of 0.39. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The firm has a 50 day moving average of $60.73 and a 200-day moving average of $44.94. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $70.40.

Insider Buying and Selling

In other Verona Pharma news, insider Kathleen A. Rickard sold 79,264 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total transaction of $661,854.40. Following the sale, the insider now owns 2,608,976 shares in the company, valued at $21,784,949.60. This trade represents a 2.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is owned by company insiders.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.